AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
AstraZeneca has out-licensed a promising respiratory compound to Insmed Inc saying the US-based group is better placed to advance AZD7986 in bronchiectasis, a rare pulmonary disorder.
AstraZeneca has out-licensed a promising respiratory compound to Insmed Inc saying the US-based group is better placed to advance AZD7986 in bronchiectasis, a rare pulmonary disorder.